Trial ID or NCT#

NCT00661674

Status

not recruiting iconNOT RECRUITING

Purpose

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril).

Official Title

Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study

Eligibility Criteria

Ages Eligible for Study: 18 Years to 35 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: Yes

Investigator(s)

Lawrence Chu, MD, MS
Lawrence Chu, MD, MS
Anesthesiologist
Professor of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM